Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2023

S 1712, the *Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2023*, would allow the FDA to quickly approve drugs, biological products, and medical devices already approved in certain countries (like those listed under section 802(b)(1) of the law or the UK) for use in the U.S., bypassing full new reviews. It directly affects drug and device manufacturers seeking to market products already approved abroad, requiring them to submit a request to the FDA for "reciprocal marketing approval." The FDA must decide within 30 days, but can deny approval if safety concerns exist or if there’s no unmet medical need in the U.S., and must report denials monthly to Congress. This streamlines access to foreign-approved treatments while maintaining FDA safety oversight and allowing Congress to block approvals via joint resolution.